Compare Harmony Gold Mining Co. (HMY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Recursion Pharmaceuticals Inc — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Harmony Gold Mining Co. is far larger — about 4.7× Recursion Pharmaceuticals Inc's market cap, and Harmony Gold Mining Co. pays a 4.63% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| HMY | RXRX | |
|---|---|---|
Market Cap | $10.02B | $2.14B |
Volume | 3,643,683 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $6.79 |
52-Week Low | $13.32 | $2.84 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | $10.07B | $1.66B |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.84, up 2.12% today, while showing strong fundamental performance with record revenue of $73.90B in 2025 and net income of $14.38B. The stock exhibits bearish technical signals with moving averages indicating selling pressure, though RSI levels suggest potential oversold conditions. Recent earnings show mixed results with two beats and two misses in the last four quarters, while analyst consensus remains cautious with 70% hold ratings.
HMY presents a value opportunity with attractive valuation multiples (P/E 6.02, EV/EBITDA 3.54) and robust profitability metrics (ROE 46.23%, net margin 29.57%). However, investors face risks from the company's significant capital expenditure plans and gold price volatility. The transition to copper production offers long-term growth potential but requires careful monitoring of execution and market conditions.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
